Unraveling DREAM-PL: A Case Report on Challenges and Management

Authors

  • Mohammed M. Barrak College of Medicine, Wasit University, Iraq
  • S. R. Al-Aidy Department of Medical Microbiology, College of Medicine, University of Wasit, Wasit, Iraq
  • Morteza Bonyadi Animal biology Department/ faculty of Natural Sciences/ University of Tabriz, Tabriz , Iran

DOI:

https://doi.org/10.32792/utq/utjsci/v11i1.1159

Abstract

An uncommon autosomal recessive condition called DREAM-PL syndrome is typified by dysmorphic facial features, renal agenesis, male ambiguous genitalia, microcephaly, polydactyly, and lissencephaly. The CTU2 gene, which is in charge of tRNA post-transcriptional modification, is mutated in the syndrome. This alteration is necessary for the correct translation of genes, and its disruption can result in several aberrant embryonic processes. The severity of DREAM-PL syndrome can vary from moderate to severe, and the clinical characteristics can be diverse. While some patients may exhibit only some of the distinguishing features, others may have all of them. The most common characteristics include ambiguous genitalia, dysmorphic facies, and microcephaly. Diagnosis of DREAM-PL syndrome is typically based on clinical signs and confirmed through genetic testing, which can identify mutations in the CTU2 gene.  Material and methodology: In the case being referred to as a study, a 37-week-old male neonate was delivered by lower segment cesarean section. The baby's birth weight was 2.760 Kg, and a heterozygous CMP mutation of the CTU2 gene was confirmed through whole-exome sequencing (WES). Unfortunately, there is currently no known cure for DREAM-PL syndrome. Result: Treatment focuses on managing the symptoms and providing supportive care. In some cases, surgical correction of birth defects may be beneficial.

References

M. Franz, L. Hagenau, L. R. Jensen, and A. W. Kuss, “Role of transfer RNA modification and aminoacylation in the etiology of congenital intellectual disability,” J. Transl. Genet. Genomics, vol. 4, pp. 50–70, 2020.

M. H. Al-Hamed et al., “Prenatal exome sequencing and chromosomal microarray analysis in fetal structural anomalies in a highly consanguineous population reveals a propensity of ciliopathy genes causing multisystem phenotypes,” Hum. Genet., pp. 1–26, 2022.

S. Leimkühler and M. O. Ogunkola, “Sulfur transferases in the pathways of molybdenum cofactor biosynthesis and tRNA thiolation in humans,” in Sulfurtransferases, Elsevier, 2023, pp. 207–236.

E. P. Kusnadi, C. Timpone, I. Topisirovic, O. Larsson, and L. Furic, “Regulation of gene expression via translational buffering,” Biochim. Biophys. Acta (BBA)-Molecular Cell Res., vol. 1869, no. 1, p. 119140, 2022.

M. Philipp, F. John, and C. Ringli, “The cytosolic thiouridylase CTU2 of Arabidopsis thaliana is essential for posttranscriptional thiolation of tRNAs and influences root development,” BMC Plant Biol., vol. 14, pp. 1–8, 2014.

J. Pothof et al., “Identification of genes that protect the C. elegans genome against mutations by genome-wide RNAi,” Genes Dev., vol. 17, no. 4, pp. 443–448, 2003.

“Exploring the Heterogeneity of Non-Syndromic Hearing Loss: A Comprehensive Review of Implicated Genes and the Role of Whole Exome Sequencing,” Univ. Thi-Qar J. Sci., vol. 10, pp. 192–199, Dec. 2023, doi: 10.32792/utq/utjsci/v10i2.1143.

R. Shaheen et al., “Biallelic variants in CTU2 cause DREAM‐PL syndrome and impair thiolation of tRNA wobble U34,” Hum. Mutat., vol. 40, no. 11, pp. 2108–2120, 2019.

W. A. Khan, “Whole-exome and whole-genome sequencing in the molecular diagnostic laboratory,” in Diagnostic Molecular Pathology, Elsevier, 2024, pp. 27–38.

H. E. Shamseldin et al., “Increasing the sensitivity of clinical exome sequencing through improved filtration strategy,” Genet. Med., vol. 19, no. 5, pp. 593–598, 2017.

D. Mahoney, J. Black, N. Dosa, A. Sakonju, and R. Lebel, “P241: Expanding the phenotype of DREAM-PL: A case report,” Genet. Med. Open, vol. 1, no. 1, 2023.

S. Kalantari and I. Filges, “Gene ontology enrichment analysis of renal agenesis: improving prenatal molecular diagnosis,” Mol. Syndromol., vol. 12, no. 6, pp. 362–371, 2021.

M. D. Ali, M. M. Barrak, R. I. Salman, and N. M. Sa’doon, “The combined effect of artemisia absinthium methanolic extract and vinblastine chemotherapy on apoptosis and decreasing chemotherapy drug concentration,” in AIP Conference Proceedings, 2023, vol. 2845, no. 1.

S. Malone-Jenkins et al., “P243: The Utah NeoSeq Project: Developing and implementing genomic sequencing in acute neonatal care,” Genet. Med. Open, vol. 1, no. 1, 2023.

R. Shaheen, Z. Al‐Salam, A. W. El‐Hattab, and F. S. Alkuraya, “The syndrome dysmorphic facies, renal agenesis, ambiguous genitalia, microcephaly, polydactyly and lissencephaly (DREAM‐PL): Report of two additional patients,” Am. J. Med. Genet. Part A, vol. 170, no. 12, pp. 3222–3226, 2016.

F. M. Al-Rubea, R. A. K. Mohammed, M. M. Barrak, and A. J. Aboob, “Molecular Detection Of Bifidobacterium Dentium From Patients With Tooth Caries,” NVEO-NATURAL VOLATILES Essent. OILS Journal| NVEO, pp. 5423–5430, 2021

Downloads

Published

2024-06-01

Issue

Section

Articles

Categories

How to Cite

Unraveling DREAM-PL: A Case Report on Challenges and Management. (2024). University of Thi-Qar Journal of Science, 11(1), 33-35. https://doi.org/10.32792/utq/utjsci/v11i1.1159